TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Platelet-Rich Plasma Therapy for Shoulder Pain in Persons With Spinal Cord Injury

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The subject is male or female, 18 to 60 years of age, inclusive.~* The subject has neurological impairment secondary to a spinal cord injury that occurred at least twelve (12) months prior to the Screening Visit and the level of the injury is between C6 and L5, inclusive.~* The subject is non-ambulatory except for exercise purposes and uses a manual or power wheelchair as his/her primary means of mobility (\> 40 hours/week).~* The subject currently has chronic shoulder pain due to rotator cuff disease in spite of at least 6 months of conservative treatment. Average shoulder pain intensity during the week leading up to the Screening Visit should be at least 5 out of 10 on an 11-point numerical rating scale (NRS; 0, no pain; 10, maximum pain imaginable), in spite of a past history of completing 6 months of conservative treatment. Rotator cuff disease will be defined as pain over the anterior shoulder, with direct palpation and pain at the shoulder with provocative tests for rotator cuff disease that is confirmed by tendinopathic changes on ultrasound imaging.~* The subject is able and willing to comply with the protocol.~* The subject is able to and has voluntarily given informed consent prior to the performance of any study-specific procedures.~Exclusion Criteria:~* The subject reports prior PRP treatment in the same shoulder;~* The subject reports a history of systemic disorders, such as diabetes or rheumatoid arthritis;~* The subject has contra-indications to the procedure, such as infection, coagulopathy, or is currently taking anti-coagulants;~* The subject reports having a glucocorticoid injection in the past 4 weeks;~* The subject is pregnant (documented by a urine pregnancy test);~* The subject has any medical condition, including psychiatric disease, which would interfere with the interpretation of the study results or the conduct of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Platelet-rich plasma therapy (Type: EXPERIMENTAL): Platelet rich plasma (PRP) describes a new technology in which platelets are isolated from a sample of a person's own blood using simple cell-separating systems such as centrifugation in order to obtain highly concentrated samples of platelets that can be re-injected into an injury site to promote healing.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial~* Male or female, age 12 to less than 18 years at the time of signing informed consent and less than 18 years at date of randomisation~* BMI corresponding to equal to or above 30 kg/m\^2 for adults by international cut-off points and equal or above the 95th percentile for age and sex (for diagnosis of obesity)~* Stable body weight during the previous 90 days before screening V2 (below 5 kg self-reported weight change)~* History of failing to lose sufficient weight with lifestyle modification as judged by the investigator and documented in subject's medical record~Exclusion Criteria:~* Pre-pubertal subjects (Tanner stage 1) at screening V2~* Type 1 diabetes mellitus (T1DM)~* Family or personal history of multiple endocrine neoplasia type 2 (MEN2)~* Medullary thyroid carcinoma (MTC)~* History of pancreatitis (acute or chronic)~* Subjects with secondary causes of obesity (i.e., hypothalamic, genetic or endocrine causes)~* Treatment with medications within 90 days before screening V2 that, based on the investigator's judgement, may cause significant weight change. This should also include treatment with any of the following medications: pramlintide, orlistat, zonisamide, topiramate, lorcaserin, phenteremine, bupropion, naltrexone, glucagon-like peptide-1 (GLP-1) receptor agonists, or metformin (used as treatment for obesity)~* Anti-diabetic treatment other than metformin~* History of major depressive disorder within 2 years before screening V2

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Liraglutide (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Short Term, High Dose Vitamin D Supplementation in Moderate to Severe COVID-19 Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. RT-PCR proven SARS-CoV-2 infection or computed tomography scan findings compatible with the COVID19 disease (bilateral multifocal ground-glass opacities ≥50%)~2. Moderate to severe COVID-19 defined by PFR ratio of \<200~3. SOFA score\>4~4. Patients with vitamin D deficiency defined as 25 (OH)D level\<20 ng/ml~5. Age\>18 years~Exclusion Criteria:~* 1. Vitamin D sufficient or already receiving vitamin D supplements 2. Active malignancy 3. Hypercalcemia, hyperparathyroidism 4. Chronic kidney disease (eGFR\<30 ml/min) 5. Pregnant and lactating women 6. Patient on mechanical ventilation at ICU admission

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): Vitamn D 6 lakh IU oral stat
- Placebo (Type: PLACEBO_COMPARATOR): Placebo equal volume/ weight

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Drug Use Investigation Of Zyvox (Linezolid) (Regulatory Post Marketing Commitment Plan)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients need to be administered Linezolid in order to be enrolled in the surveillance.~Exclusion Criteria:~* Patients not administered Linezolid.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- linezolid (Zyvox) (Type: None): Patients taking Linezolid.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intensive Alveolar Recruitment Protocol After Cardiac Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Immediate postoperative period of myocardial revascularization and/or heart valve surgery (aortic and/or mitral)~* Age \> 18 years and \< 80 years~* No previous pulmonary disease~* Left ventricular ejection fraction \> 35%~* Body mass index \< 40 kg/m2~* Oxygen index (PaO2/FiO2) \< 250~* Corrected volemic status (negative raising legs mean arterial pressure \[MAP\] variation \< 10%)~* Written inform consent~Exclusion Criteria:~* MAP (mean arterial pressure) \< 60 mmHg~* Noradrenaline \> 2 micrograms/Kg/min~* Acute arrhythmias~* Blooding associated to hemodynamic instability~* Need of re-surgery and/or mechanical circulatory assistance~* Suspicion of neurological alteration~* Chest tube with persistent air leak

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Intensive Alveolar Recruitment (Type: EXPERIMENTAL): Recruitment with opening pressures of 45 cmH2O in the airways.
- Moderate Alveolar Recruitment (Type: ACTIVE_COMPARATOR): Recruitment with opening pressures of 20 cmH2O in the airways.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of the Transfer of Using Levonorgestrel Intrauterine System (LNG IUS) as a Contraceptive to Using it as Part of Hormone Replacement Therapy (HRT).

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Women with intact uterus, regular menstrual cycles and no previous or current climacteric symptoms.~Exclusion Criteria:~* Pregnancy or lactation.~* Previous pelvic infections.~* Abnormal bleeding.~* Abnormal uterine cavity.~* Uterine polyps.~* Genital cancer.~* Liver diseases.~* Alcoholism or drug abuse.

- Gender: FEMALE
- Minimum Age: 46 Years
- Maximum Age: 51 Years
- Healthy Volunteers: f

Study Arms:
- LNG IUS (Type: EXPERIMENTAL): Levonorgestrel Intrauterine System (LNG IUS) (initial in vitro release 20 µg/24h) intrauterine for minimum of 9 months and maximum of 60 months - 2 phases: a) Contraception Phase b) Hormone-Replacement Therapy (HRT) Phase. For outcome measures (vaginal bleeding variables), five 90-day Reference Periods were defined, which were used for comparison during statistical analysis: Reference Period -1 in Contraception Phase; Reference Periods 1-4 in HRT Phase. 90-day reference periods for analyzing vaginal bleeding data are defined by World Health Organization (WHO) guideline. Reference Period -1 is the last 90-day reference period that the subject had before starting the HRT. Reference Period 1 covers the first 90-days of the HRT phase, Reference Period 2 covers days 91 to 180, Reference Period 3 days 181 to 270, and Reference Period 4 days 271 to 360 of the HRT phase.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Must have a confirmed diagnosis of relapsing multiple sclerosis (RMS), as defined by McDonald criteria 1 through 4 (Polman, 2005)~* Must have an EDSS score between 0.0 and 5.0.~* Must have experienced at least 2 relapses that have been medically documented within the last 3 years with at least one occurring in the last 12 months~Key Exclusion Criteria:~* Other chronic disease of immune system, malignancies, urologic, pulmonary, gastrointestinal disease~* Pregnant or nursing women~* Prior treatment with interferon could not exceed 4 weeks and subjects must have discontinued interferon treatment 6 months prior to Baseline~NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo every 2 weeks for 48 weeks followed by 125 µg peginterferon beta-1a subcutaneously every 2 or 4 weeks for 48 weeks.
- Peginterferon Beta-1a Q2W (Type: EXPERIMENTAL): 125 µg peginterferon beta-1a subcutaneously every 2 weeks (Q2W) for 96 weeks.
- Peginterferon Beta-1a Q4W (Type: EXPERIMENTAL): 125 µg peginterferon beta-1a subcutaneously every 4 weeks (Q4W) for 96 weeks. Participants received a placebo injection 2 weeks after each active injection (in order to maintain the blind with Q2W arm).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed active head lice infestation~Exclusion Criteria:~* Allergy to pediculicides or hair care products~* Scalp conditions other than head lice~* Previous head lice treatment within the past 4 weeks~* Current antibiotic treatment

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Malathion Gel (Type: EXPERIMENTAL): Malathion gel 0.5% 30 minute application
- Nix Creme Rinse (Type: ACTIVE_COMPARATOR): Nix applied to scalp for 10 minutes

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparing Synthetic Bone Alone Versus Synthetic Bone With Bone Marrow in Bone Lesions

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a benign bone lesion requiring surgical curettage~Exclusion Criteria:~* Patients with infection, bone marrow disorders, or other contraindications to use of supplemental bone marrow aspiration as well as those who prefer autologous or allogeneic graft material alone (without synthetic filler) would be excluded.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vitoss with bone marrow aspirate (Type: EXPERIMENTAL): Addition of Vitoss to the bone marrow aspirate
- Vitoss Alone (Type: ACTIVE_COMPARATOR): vitoss alone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vinpocetine Inhibits NF-κB-dependent Inflammation in Acute Ischemic Stroke Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* \>18 years of age~* Anterior-circulation ischemic stroke: All patients had symptoms of focal neurological deficits and simultaneous radiological evidence (magnetic resonance imaging, MRI) of an ischemic brain lesion~* measurable neurological deficit (NIHSS \> 5)~* interval between symptom onset and admission more than 4.5 hours and less than 48 hours. That is, all patients we recruited were beyond the 4.5 hours of symptom onset and, therefore, past the accepted time-window for thrombolytic therapy~Exclusion Criteria:~* hemorrhagic stroke and severe hemorrhage in other organs~* other diseases of the central nervous system (CNS)~* diabetes mellitus~* tumor or hematological systemic diseases~* any infection before acute ischemic stroke~* concomitant use of antineoplastic or immune modulating therapies~* contraindication to MRI

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- vinpocetine group (Type: ACTIVE_COMPARATOR): Aspirin, 10mg, po and 30 mg of the vinpocetine by intravenous infusion once daily, for fourteen consecutive days
- Control group (Type: PLACEBO_COMPARATOR): Patients will receive aspirin only.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dose Response of Intravenous Sincalide(CCK-8) for Gallbladder Emptying

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy males and females between ages 18-65 years of age with no gastrointestinal disease as screened by the Mayo Clinic GI Disease Screening Questionnaire~2. Subjects with high probability for compliance and completion of the study~3. Normal liver function tests and amylase~4. Normal ultrasound of the gallbladder~Exclusion Criteria:~1. Prior GI surgery, excluding appendectomy~2. Surgery within the past 3 months~3. BMI \> 35~4. Female of childbearing age who is not practicing birth control and/or is pregnant or lactating. (Confirm with urine pregnancy test)~5. Cardiovascular, endocrine, renal, gastrointestinal, or other chronic disease likely to affect motility. This includes diabetes, renal insufficiency, gastroesophageal reflux disease, gastroparesis, irritable bowel syndrome, prior peptic ulcer disease.~6. GI symptoms such as heartburn, chest pain, dysphagia, abdominal pain, nausea, vomiting, constipation, diarrhea.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Experimental Sequence ABC (Type: ACTIVE_COMPARATOR): CCK-8 0.02 mg/kg over 15 minutes, followed by CCK-8 0.02 mg/kg over 30 minutes, followed by CCK-8 0.02 mg/kg 60 minutes, with at least 2 days between each infusion
- Experimental Sequence ACB (Type: ACTIVE_COMPARATOR): CCK-8 0.02 mg/kg over 15 minutes, followed by CCK-8 0.02 mg/kg over 60 minutes, followed by CCK-8 0.02 mg/kg 30 minutes, with at least 2 days between each infusion
- Experimental Sequence BAC (Type: ACTIVE_COMPARATOR): CCK-8 0.02 mg/kg over 30 minutes, followed by CCK-8 0.02 mg/kg over 15 minutes, followed by CCK-8 0.02 mg/kg 60 minutes, with at least 2 days between each infusion
- Experimental Sequence BCA (Type: ACTIVE_COMPARATOR): CCK-8 0.02 mg/kg over 30 minutes, followed by CCK-8 0.02 mg/kg over 60 minutes, followed by CCK-8 0.02 mg/kg 15 minutes, with at least 2 days between each infusion
- Experimental Sequence CAB (Type: ACTIVE_COMPARATOR): CCK-8 0.02 mg/kg over 60 minutes, followed by CCK-8 0.02 mg/kg over 15 minutes, followed by CCK-8 0.02 mg/kg 30 minutes, with at least 2 days between each infusion
- Experimental Sequence CBA (Type: ACTIVE_COMPARATOR): CCK-8 0.02 mg/kg over 60 minutes, followed by CCK-8 0.02 mg/kg over 30 minutes, followed by CCK-8 0.02 mg/kg 15 minutes, with at least 2 days between each infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Calcifediol in the Treatment of COVID 19

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 and \< 90 years.~* Diagnosis confirmed by positive polymerase chain reaction (PCR) for COVID-19.~* Radiological image compatible with pulmonary involvement by COVID-19.~* Admission to Reina Sofia university Hospital (HURS) Pneumology Department.~Exclusion Criteria:~* Patients for whom electronic medical record data cannot be collected.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- Calcifediol (Type: None): None
- Best therapy available (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 400mcg Sublingual Misoprostol as First Line Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* uterine size less than 12 weeks lmp~* open cervical os~* current or past vaginal bleeding~* willing to provide contact information for follow-up~* over 18 or with guardian consent~Exclusion Criteria:~* suspicion of ectopic pregnancy~* intrauterine device in place~* bad general health (infection, anemia, shoc)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- misoprostol (Type: EXPERIMENTAL): 400 mcg misoprostol sublingually

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Therapy of Toxic Optic Neuropathy Via Combination of Stem Cells With Electromagnetic Stimulation

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Cases poisoned with a toxic agent within 3 months~* Patients with BCVA better than 35 letters~* Any degree of visual field loss~* Patients over 18 years old~Exclusion Criteria:~* Cases poisoned with a toxic agent more than 3 months~* Patients with BCVA less than 35 letters: to perform the visual field test correctly~* Neurological sequelae that cannot be cooperated~* Smoking

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- WJ-MSC combine witf rEMS (Type: ACTIVE_COMPARATOR): WJ-MSC was applied first to the patients after necessary preparations. rEMS application was started 10 days after WJ-MSC application.
- Only rEMS (Type: ACTIVE_COMPARATOR): rEMS applications were repeated 10 times with a 1-week interval.
- Only WJ-MSC (Type: ACTIVE_COMPARATOR): WJ-MSC was applied only one time for both eyes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete